Algae Biosciences Corporation Announces Resignation of CEO and CFO and Appointment of New CEO and CFO

Calgary, Alberta--(Newsfile Corp. - June 28, 2013) - Algae Biosciences Corporation (TSXV: ABV) ("AlgaeBio") announced today that Mr. Andrew Ayers has resigned as President, CEO and director of the Company and its subsidiary, effective immediately. Mr. Ayers has served as President, CEO and director of the Company since foundation. Additionally, the Company announced today that Mr. Robert Thompson has resigned as CFO and director of the company and its subsidiary, effective immediately.

The company announced that Mr. Ward Marlatte has been appointed CEO, secretary and director of the Company. Additionally, Mr. Marc Stachiw has been appointed interim CFO and director of the Company.

ABOUT ALGAE BIOSCIENCES CORPORATION: AlgaeBio is a Canadian biotechnology company that researches, develops, and manufactures products from micro and macro algae such as nutraceuticals, food additives, and pharmaceuticals. With access to algae growing conditions, exclusive aquaculture access to a brine water supply, and advanced proprietary technology, AlgaeBio produces human and animal consumable products, as well as offering advanced algae-based products and technologies for distribution. AlgaeBio owns and operates production facilities near Holbrook, Ariz., and is listed on the TSX Venture Exchange (TSXV: ABV).

For more information:
Kevin Blanchette
Director
Algae Biosciences Corporation
E-mail: kevinblanchetteFshaw.ca

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the content of this release.

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAWS.